We are thrilled to announce that Biocytogen will attend the SBME Symposium on June 2nd, in Vancouver, Canada. Join us for a day of presentations on the latest biomedical research findings and networking opportunities. Visit our booth to grab some swag and learn more about our humanized mouse models and preclinical services!
What is SBME?
Founded in 2017, the School of Biomedical Engineering (SBME) is an interfaculty institution where biology, medicine, and engineering converge to transform healthcare. Their strategic initiatives and future-orientated educational programming are driving innovation and accelerating the growth of Canada’s biotech ecosystem.
Event Overview
Date: June 2nd, 2026
Venue: Gordon B. Shrum Building, 6088 University Blvd, Vancouver, BC V6T 1Z3, Canada
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in Vancouver, Canada!
